Clinical trial
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
ClinicalTrials.gov ID: NCT05556096
Sponsor: Alexion
Information provided by: Alexion (Responsible Party)
Last Update Posted: 2023-09-07
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
OFFICIAL TITLE
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
INTERVENTION / TREATMENT
Combination Product: ALXN1720
Combination Product: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) | 2022-11-21 |
| Primary Completion (Estimated) | 2025-08-05 |
| Study Completion (Estimated) | 2027-07-07 |
| Enrollment (Estimated) | 254 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers | ALXN1720-MG-301 2022-000460-21 (EudraCT Number) |